3.2. Effect of cryotherapy on the incidence of persistent CIPN
cancer, CIPN
REGRESSION, CANCER
In all 38 patients, persistent CIPN was demonstrated in 10 (26.3%). The incidence of persistent CIPN was 15.8% and 36.8% in the cryotherapy and control group, respectively, indicating a numerically but not significantly lower incidence of persistent CIPN in the cryotherapy group compared with the control group (A multivariate logistic regression analysis to evaluate the association between clinicopathological factors and the incidence of persistent CIPNCI = confidence interval, CIPN = chemotherapy induced peripheral neuropathy, HR = hazard ratio. A multivariate logistic regression analysis was used to evaluate predictive factor for acute and persistent CIPN.A 6-point or more decrease in the total of FACT-NTX score from baseline is regarded as occurrence of CIPN.The individual FACT-NTX scores at baseline, completion of weekly paclitaxel-based chemotherapy (early CIPN), and more than 1 year after the treatment completion (persistent CIPN) in the (A) control group and (B) cryotherapy groups. CIPN = chemotherapy-induced peripheral neuropathy, FACT-NTX = functional assessment of cancer therapy-neurotoxicity.The other clinicopathological factors were not significant predictors of persistent CIPN. Regarding compliance to cryotherapy, persistent CIPN was recognized in 3 (50%) of 6 patients with incomplete compliance and 3 (23%) of 13 patients with complete compliance, respectively.